Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study

Objectives To investigate the association between exposure to biologics during pregnancy and serious infections in mothers and infants. Design Retrospective cohort study. Setting Population-based. Participants Women with one or more autoimmune diseases identified by International Classification of Diseases 9th/10th revision codes in healthcare administrative databases in British Columbia, Canada, who had pregnancies ending in a live or stillbirth between 1 January 2002 and 31 December 2012. Women were defined as exposed if they had at least one biologic prescription during pregnancy, and infants born to these women were considered exposed in utero. Disease-matched women with no biologics prescriptions during pregnancy, and their infants, comprised the unexposed groups. Primary outcome measures Serious infections requiring hospitalisation. Results Over the 10-year study period, there were 6218 women (8607 pregnancies) who had an autoimmune disease diagnosis, of which 90 women were exposed to biologics during pregnancy, with 100 babies born to these women. Among women exposed to biologics during pregnancy, occurrence of serious postpartum infections were low, ranging from 0% to 5%, depending on concomitant exposures to immunosuppressants. In multivariable models using logistic regression, the OR for the association of biologics exposure with serious maternal postpartum infections was 0.79 (95% CI 0.24 to 2.54). In infants exposed to biologics in utero, occurrence of serious infections during the first year of life ranged from 0% to 7%, depending on concomitant exposures to immunosuppressants in utero. Multivariable models showed no association between biologics exposure in utero and serious infant infections (OR 0.56, 95% CI 0.17 to 1.81). Conclusions These population-based data suggest that the use of biologics by women with autoimmune diseases during pregnancy is not associated with an increased risk of serious infections in mothers, during post partum or in infants during the first year of life.

[1]  L. Lynd,et al.  Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population‐Based Cohort Study , 2018, Arthritis care & research.

[2]  M. Blomberg,et al.  Postpartum infection in relation to maternal characteristics, obstetric interventions and complications , 2018, Journal of perinatal medicine.

[3]  J. Gisbert,et al.  Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study , 2018, The American Journal of Gastroenterology.

[4]  M. Haugen,et al.  Breastfeeding and Infant Hospitalisation for Infections: Large Cohort- and Sibling Analysis. , 2017, Journal of pediatric gastroenterology and nutrition.

[5]  S. Hernández-Díaz,et al.  Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study , 2017, British Medical Journal.

[6]  Terry S Baker,et al.  Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. , 2016, Journal of reproductive immunology.

[7]  R. Fischer-Betz,et al.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.

[8]  C. Gordon,et al.  BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. , 2016, Rheumatology.

[9]  M. Mathai,et al.  New WHO guidance on prevention and treatment of maternal peripartum infections. , 2015, The Lancet. Global health.

[10]  Masaru Ishii,et al.  The expanding role of immunopharmacology: IUPHAR Review 16 , 2015, British journal of pharmacology.

[11]  P. Tugwell,et al.  Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis , 2015, The Lancet.

[12]  C. Nelson-Piercy,et al.  High-risk pregnancy and the rheumatologist. , 2015, Rheumatology.

[13]  P. Goulder,et al.  Sex Differences in Pediatric Infectious Diseases , 2014, The Journal of infectious diseases.

[14]  Y. Shoenfeld,et al.  Biologic therapy for autoimmune diseases: an update , 2013, BMC Medicine.

[15]  W. Dupont,et al.  Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections , 2012, Journal of Allergy and Clinical Immunology.

[16]  D. Scott.  Biologics‐Based Therapy for the Treatment of Rheumatoid Arthritis , 2012, Clinical pharmacology and therapeutics.

[17]  S. Shariq,et al.  Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. , 2010, Journal of Crohn's & colitis.

[18]  R. Giordano,et al.  Postpartum period: three distinct but continuous phases. , 2010, Journal of prenatal medicine.

[19]  P. Catalano,et al.  New guidelines for weight gain during pregnancy: what obstetrician/gynecologists should know. , 2009, Current opinion in obstetrics & gynecology.

[20]  J. Avorn,et al.  High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.

[21]  C. Gordon,et al.  Biologic therapy and pregnancy outcomes in women with rheumatic diseases. , 2009, Arthritis and rheumatism.

[22]  S. Kane,et al.  Placental Transport of Immunoglobulins: A Clinical Review for Gastroenterologists Who Prescribe Therapeutic Monoclonal Antibodies to Women During Conception and Pregnancy , 2009, The American Journal of Gastroenterology.

[23]  S. Targan,et al.  Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  R. Platt,et al.  Epidemiology of and surveillance for postpartum infections. , 2001, Emerging infectious diseases.

[25]  L. de Jong-van den Berg,et al.  Do Pregnant Women Report Use of Dispensed Medications? , 2001, Epidemiology.

[26]  C. Anderson,et al.  The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Johnson,et al.  Detection of IgG bound within human trophoblast. , 1982, Journal of immunology.

[28]  R. Gibbs.  Clinical Risk Factors for Puerperal Infection , 1980, Obstetrics and gynecology.

[29]  F. W. Brambell.  The transmission of immunity from mother to young and the catabolism of immunoglobulins. , 1966, Lancet.